在临床实践中,对Tildrakizumab治疗斑块牛皮患者的3年经验
Martina Burlando1,2, Ilaria Salvi3,4, Aurora Parodi3,4
1Division of Dermatology, Department of Health Sciences-DISSAL, University of Genoa, Genoa, Italy. martina.burlando@unige.it.
Dermatology and therapy
|August 27, 2024
概括
提尔德拉基祖马布有效治疗中度至重度的斑块性牛皮,许多患者在36周内达到显著的牛皮严重程度指数 (PASI) 100清除,并在现实临床实践中保持长达三年的清除.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 随机试验确定了tildrakizumab在斑块性牛皮的疗效和安全性.
- 现实世界的数据对于优化生物药物使用至关重要.
- 对蒂尔德拉基祖马布的长期临床经验是有价值的.
研究的目的:
- 在现实环境中评估蒂尔德拉基祖马布在中度至重度斑块性牛皮患者的长期疗效.
- 为了评估对蒂尔德拉基祖马布治疗的时间反应的持久性.
主要方法:
- 一个长期的回顾性观察性研究.
- 包括136名患有中度至重度斑块性牛皮的成年患者,这些患者接受了提尔德拉基祖马布治疗.
- 数据是在现实生活中的临床环境中收集的.
主要成果:
- 牛皮地区严重性指数100 (PASI 100) 在16周时被51.2%的患者实现,从36周到3年时达到66.9%-64.5%.
- 平均PASI分数从基线时的12.6提高到36周后的1.8,保持稳定长达3年.
- 患有较短牛皮病史的患者在36周内实现PASI 90或PASI 100的可能性更高.
结论:
- 提尔德拉基祖马布100毫克在中度至重度的斑块性牛皮患者中,在很大比例的患者中提供持续的PASI 100.
- 在现实临床实践中,治疗疗效保持长达3年.
- 早期的蒂尔德拉基祖马布治疗可能与更好的结果有关.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
98
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
98
01:29Inflammatory Bowel Disease IV: Pharmacological Management
123
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
123
01:24T Cell Types and Functions
963
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
963
01:29Drugs for Treatment of Ulcerative Colitis in IBD
130
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
130